for both BM and PB; Figure 1d ). Standard risk cases expressed WT1 on higher level compared with high risk group (Po0.0001 for both BM and PB). We could not prove any relation of WT1 level to age, sex or d15 treatment response. Neither did the expression of WT1 correlate with survival characteristics of our cohort of childhood AML; patients with high and low initial level of WT1 had the same relapse-free survival probability (Figure 1e ).
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study Leukemia (2013) 27, 1196-1201; doi:10.1038/leu.2012.292
Chronic graft-versus-host disease (CGVHD) is one of the most debilitating complications post hematopoietic cell transplant (HCT). Several studies have evaluated the factors affecting survival in CGVHD, [1] [2] [3] [4] [5] [6] [7] [8] most utilizing the older definition of CGVHD, where patients with any symptoms of GVHD (acute or chronic) may be classified as CGVHD if found symptomatic beyond day 100 post HCT. However, the new National institutes of health (NIH) consensus guidelines have redefined the criteria for CGVHD diagnosis and staging 9 based on the actual symptoms at presentation, and excludes the patients with persistent, recurrent or late acute graft-versus-host disease (AGVHD) who were previously considered to have CGVHD. The CGVHD consortium follows a large multicenter prospectively enrolled cohort of CGVHD patients utilizing NIH consensus guidelines for assessments. 10 Several reports from this consortium have identified factors affecting survival, including global severity, thrombocytopenia, karnofsky performance score and overlap syndrome. 11, 12 Prior AGVHD has been associated with a higher mortality in patients who develop CGVHD, 1, 3 indicating that these patients may be more debilitated and hence suffer worse outcome. However, the clinical and prognostic importance of prior AGVHD on subsequent CGVHD in the current era, using NIH diagnostic and staging criteria, is unknown. We evaluated the significance of prior AGVHD on CGVHD presentation, overall response and survival in a contemporary cohort of CGVHD patients prospectively enrolled by the CGVHD consortium. Cases enrolled in the consortium could be incident (enrollment o3 months after diagnosis) or prevalent (enrollment X3 months after diagnosis). 10 Detailed CGVHD assessments were performed reflecting the recommendations of the NIH consensus conference, 9, 13 and are published in the cohort study rationale and design summary. 10 Prior AGVHD was considered to be present if maximum grade I À IV was reported. Comparisons were performed between two groups: Prior AGVHD and no prior AGVHD. Statistical comparisons between groups were made with the two-sample t-test for continuous variables, and w 2 -test for categorical variables. Spearman correlation coefficient (r,) and simple k-statistics were used to describe rank correlation and agreement between AGVHD Accepted article preview online 10 october 2012; advance online publication, 26 October 2012
Letters to the Editor (15) 46 (14) 28 (17) 2 9 (2) 5 (2) 4 (2) 3 6 (1) 5 (2) 1 (1) 4 12 (2) 7 (2) Letters to the Editor and CGVHD overall severity scores, and skin, gastrointestinal (GI) and liver severity. Survival was estimated by the Kaplan À Meier method. 14 Overall survival was calculated from enrollment; and non-relapse mortality (NRM) was defined as death without prior relapse. Failure-free survival was defined as survival without prior relapse or adding new systemic medications to treat CGVHD. Cox regression 15 was used for multivariate analysis of survival relative to presence or absence of prior AGVHD and other risk factors.
The total cohort included 496 patients: 329 with prior AGVHD and 167 with no prior AGVHD (de novo CGVHD) ( Table 1 ). The prior AGVHD and de novo CGVHD groups did not differ with respect to time between HCT and CGVHD diagnosis, or time between HCT and enrollment. The proportion of patients with classic and overlap CGVHD, and the distribution of CGVHD global severity (mild, moderate and severe CGVHD), using clinician or patient reports and NIH scores, was similar. These observations support the hypothesis that CGVHD in patients with prior AGVHD does not Letters to the Editor differ fundamentally from de novo CGVHD. In particular, prior AGVHD was not associated with AGVHD manifestations at the time of CGVHD diagnosis (overlap syndrome). There were some differences between prior AGVHD and de novo CGVHD groups: myeloablative condition, a mismatched or unrelated donor and thrombocytopenia were more frequent in those with prior AGVHD. No further differences were observed between the two groups, including frequency of organ involvement, functional assessments or patient-reported outcomes.
ACUTE GVHD ORGAN CHRONIC GVHD ORGAN CORRELATION
Overall severity of prior AGVHD (including non-involvement) did not correlate well with overall NIH-calculated severity of CGVHD at study enrollment (r ¼ 0.04). Similarly, AGVHD symptom severity (including non-involvement) of skin (r ¼ 0.01), gut (r ¼ 0.14) and liver (r ¼ 0.06) showed little correlation with CGVHD organspecific involvement. Dichotomizing severity scores as p1 versus 41, the agreement between AGVHD and CGVHD severity was poor. The simple k-statistics were 0.03 for overall global severity, À 0.05 for skin, 0.02 for GI and 0.01 for liver comparisons, all of which were considered as poor agreement.
RESPONSE TO TREATMENT AT 6 AND 12 MONTHS FROM COHORT ENROLLMENT
No difference was observed in NIH-calculated response rates between those with and without prior AGVHD for both 6 months (n ¼ 302, P ¼ 0.88) and 12 months (n ¼ 228, P ¼ 0.77) assessments. In all 36% of patients with no prior AGVHD versus 37% with prior AGVHD had complete response (CR) or partial response (PR) at 6 months, and 33% versus 35% at 12 months.
SURVIVAL FROM ENROLLMENT
Of the 496 patients in this cohort, 84 (17%) have died with median follow-up time for survivors of 20 months (range 0 À 48). Two-year survival probability was similar at 0.83 (95% confidence interval (CI): 0.77-0.87) for those with prior AGVHD, and 0.79 (95% CI: 0.71-0.85) for those without prior AGVHD. The multivariate analysis was performed, restricting the study sample to incident cases only (n ¼ 281), to address potential survivor bias, as patients who die soon after developing CGVHD are not enrolled into the cohort as prevalent cases. Prior AGVHD was not a predictor of overall survival in either univariate (hazard ratio (HR): 0.74, 95% CI: 0.41-1.31, P ¼ 0.30) or multivariate ( Table 2 , HR: 0.68, 95% CI: 0.35-1.30, P ¼ 0.24) analysis. We tested for and did not find a significant interaction between prior AGVHD and CGVHD type (classic versus overlap). Overall survival was predicted by several manifestations at enrollment, including presence of thrombocytopenia, a lower karnofsky performance status, a higher total bilirubin and a higher NIH severity score. There was no evidence of association between prior AGVHD and NRM (HR: 0.73, 95% CI: 0.30-1.74, P ¼ 0.47) or failure-free survival (HR: 1.15, 95% CI: 0.79-1.66, P ¼ 0.47) in multivariate models with the same covariates as for overall survival. We next repeated the analysis in the whole group, including both incident and prevalent cases (Supplementary Table S1 ). No evidence of association was found between prior AGVHD and overall survival (HR: 0.96, 95% CI: 0.60-1.55, P ¼ 0.87). The analysis was repeated after including only incident patients with more severe AGVHD (grade II-IV) in the prior AGVHD group. Results were similar to the current analyses (HR: 0.67, 95% CI: 0.35-1.27, P ¼ 0.21).
We undertook this analysis to evaluate the impact of prior AGVHD in a prospectively enrolled cohort of patients with CGVHD using NIH criteria. 9 In our analysis, prior AGVHD was not associated with CGVHD characteristics, presence of overlap or classic symptoms, global CGVHD severity, responsiveness to treatment, quality of life, functional status, NRM or survival.
There could be several reasons for our findings. Under the new CGVHD diagnostic criteria, late, persistent and recurrent AGVHD are not automatically considered CGVHD. These patients are not included in our cohort and may account for the poor prognosis associated with prior AGVHD seen in other studies that used older diagnostic criteria. Another possibility is that patients with more severe CGVHD may have higher early mortality and may not survive to be enrolled in our study. To address this concern, we restricted our multivariate analysis to include only the incident cases, who were enrolled within 3 months of CGVHD diagnosis and demonstrated no effect of prior AGVHD. We then repeated the analysis in the whole cohort (incident and prevalent) and our results were similar (Supplementary Table S1 ). In the whole cohort, similar to a prior study, 12 we also noted an adverse impact of overlap syndrome on overall survival. In the current analysis, in the incident patients only, the frequency of overlap patients was much higher (n ¼ 250, 89%) with only 11% patients with classic CGVHD, which could account for the nonsignificant result. It is unlikely that including the overlap variable in the analysis is masking the importance of prior AGVHD, as there was no correlation between prior AGVHD and overlap syndrome at the time of enrollment.
Our results suggest that once a patient develops CGVHD, according to the NIH diagnostic criteria, presence of prior AGVHD is not an adverse risk factor. This is in contradiction to a recently published large analysis from the CIBMTR, in which prior grade II-IV AGVHD was an adverse prognostic factor for survival and transplant related mortality (TRM). 3 However, the CIBMTR (Center for international blood and marrow transplant research) study defined CGVHD according to the older criteria based on time since transplantation and involved mostly younger patients (median age 36 years) undergoing myeloablative conditioning (89%) and mostly calcineurin inhibitor-based GVHD prophylaxis. Median follow-up in our cohort was 20 months compared to 73 months in the CIBMTR study. Our cohort was accrued from nine centers with an interest and focus on CGVHD, and is also more recent, therefore, differences in patient populations may also explain the differing results for AGVHD as a risk factor.
Progressive onset of CGVHD has been found to be an adverse factor for survival and TRM. 4 We tried to investigate this issue, but patients are not enrolled in our cohort until they are diagnosed with CGVHD by NIH diagnostic criteria. Retrospective review of medical records before patients were enrolled into the cohort showed that most documentation was inadequate to distinguish between progressive onset and interrupted onset.
In conclusion, our results suggest that presence of prior AGVHD does not affect the clinical presentation of either classic or overlap CGVHD and is not associated with lower survival or less responsive CGVHD. Instead, what seems to matter for predicting prognosis is the current status of CGVHD. Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib and dasatinib, are currently approved for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients. Although these drugs result in excellent responses in most patients, significant interpatient variability in overall response is observed. We have previously demonstrated that the degree of kinase inhibition achieved in vitro and in vivo is a critical variable of imatinib response 1,2 in CP-CML patients, and that the degree of kinase inhibition mediated is closely related to the intracellular concentration of the drug achieved. 3 Importantly, the intracellular drug concentration is a result of the net effects of drug influx/efflux and plasma concentration, which can be influenced by many factors including concomitant therapies.
CONFLICT OF INTEREST
TKIs are generally well tolerated, however, side effects have been reported some of which, such as gastrointestinal problems, necessitate therapeutic intervention. Although the use of proton pump inhibitors (PPIs), including pantoprazole, esomeprazole and others, is contraindicated in patients taking dasatinib (at the direction of Bristol-Myers Squibb (BMS) due to the risk of reduced dasatinib exposure), they are widely prescribed in the greater community, and also frequently taken by patients on imatinib and nilotinib to control the documented gastric side effects. Data from the recent ENESTnd study indicated that up to 24% of patients treated with nilotinib concurrently received PPIs or H2 blockers. 4 Furthermore, up to 34% of patients treated on study CAMN107A2101 received these drugs, indicating that their coprescription is not uncommon. 4 PPIs have been reported to interact with the drug efflux transporters, ABCB1 and ABCG2. In this context, PPIs have been found to be both inhibitors and substrates. [5] [6] [7] We and others 3, 8, 9 have demonstrated that imatinib and nilotinib also interact with both ABCB1 and ABCG2 providing impetus for further investigation. As PPI's, and TKI, are also metabolized by cytochrome 450, drug interactions could potentially also occur during metabolism. Recently, Yin et al. 4 demonstrated only a modest decrease in nilotinib concentration when PPIs were coadministered with nilotinib in normal controls, suggesting that the increase in gastric pH afforded by the use of PPIs has no Accepted article preview online 16 October 2012; advance online publication, 20 November 2012
